Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab From toxicity assessment to adaptive safety care: implementing comprehensive fast track safety evaluation for anticancer drug development ESMO Open Population Scale Identification of Differential Adverse Events Before and During a Pandemic Zitnik Lab In 2023, the FDA banned 19 peptides from compounding pharmacies. No specific safety incident. No clear signal. Just a regulatory decision that pushed millions of patients toward gray market suppliers and overseas Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database Scientific Reports Clinical spectrum and evolution of immune checkpoint inhibitors toxicities over a decadea worldwide perspective eClinicalMedicine